These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10917001)

  • 1. [Bone metabolic markers and use of vitamin D in dialysis. Multicenter survey. (II). Collaborative Centers of the Multicenter Study on Renal Osteodystrophy].
    Díaz Corte C; Rodríguez A; Naves ML; Fernández Martín JL; Cannata JB
    Nefrologia; 2000; 20(3):244-53. PubMed ID: 10917001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal osteodystrophy in Spain. Multicenter survey. (I). Collaborative Centers of the Multicenter Study on Renal Osteodystrophy].
    Díaz Corte C; Naves ML; Rodríguez A; Barreto S; Gómez C; Cannata JB
    Nefrologia; 2000; 20(3):234-43. PubMed ID: 10917000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal osteodystrophy Guidelines].
    Messa P;
    G Ital Nefrol; 2003; 20 Suppl 24():S83-95. PubMed ID: 14666505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
    Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influences of method of calcium correction and the timing of blood collection on application of the K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan.
    Yokoyama K; Katoh N; Kasai K; Kubo H; Murai S; Shoji R; Imamura N; Saika S; Yumita S; Ishida M; Takasu S; Kono T; Yoshida Y; Wakabayashi T; Kimua Y; Hosoya T
    Ther Apher Dial; 2006 Jun; 10(3):257-61. PubMed ID: 16817790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
    Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
    Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A
    Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoalbuminemia differently affects the serum bone turnover markers in hemodialysis patients.
    Zheng CM; Wu CC; Lu CL; Hou YC; Wu MS; Hsu YH; Chen R; Chang TJ; Shyu JF; Lin YF; Lu KC
    Int J Med Sci; 2019; 16(12):1583-1592. PubMed ID: 31839746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients.
    Navarro JF; Mora C; Jiménez A; Torres A; Macía M; García J
    Am J Kidney Dis; 1999 Jul; 34(1):43-8. PubMed ID: 10401014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.